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 Five years of adjuvant tamoxifen has been the standard endocrine 
treatment for early-stage breast cancer for several decades. Adjuvant 
endocrine therapy following primary surgery for breast cancer 
reduces the risk of recurrence and increases overall survival beyond 
the period of treatment for women with estrogen receptor (ER) –
 positive disease ( 1 ). Mature meta-analysis data on 15-year recur-
rence and breast cancer mortality probabilities demonstrate 
substantial and persistent benefits of receiving adjuvant tamoxifen 
compared with no adjuvant treatment ( 1 ). Most of the effect of 
adjuvant tamoxifen on recurrence is seen during the first 5 years 
after surgery, when tamoxifen is generally still administered, with 
gains in recurrence-free survival of 11.4%. However, many women 
who are treated with 5 years of adjuvant tamoxifen still develop 
recurrent disease, and most of the effect of adjuvant tamoxifen on 
breast cancer mortality occurs after the fifth year after surgery. 
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 ARTICLE 
 Extended Adjuvant Therapy With Anastrozole Among 
Postmenopausal Breast Cancer Patients: Results 
From the Randomized Austrian Breast and Colorectal 
Cancer Study Group Trial 6a 
 Raimund  Jakesz ,  Richard  Greil ,  Michael  Gnant ,  Marianne  Schmid ,  Werner  Kwasny ,  Ernst  Kubista , 
 Brigitte  Mlineritsch ,  Christoph  Tausch ,  Michael  Stierer ,  Friedrich  Hofbauer ,  Karl  Renner ,  Christian  Dadak , 
 Ernst  Rücklinger ,  Hellmut  Samonigg 
 On behalf of the Austrian Breast and Colorectal Cancer Study Group 
  Background  Clinical trial data have shown that among breast cancer patients who were disease free after 5 years of 
adjuvant treatment with tamoxifen, further extended treatment with the nonsteroidal aromatase inhibitor 
letrozole reduces breast cancer recurrence. We examined the efficacy and tolerability of extended adju-
vant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had com-
pleted 5 years of adjuvant therapy. 
  Methods  Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a is an extension of ABCSG Trial 6, in 
which hormone receptor – positive postmenopausal patients received 5 years of adjuvant tamoxifen, with 
or without the aromatase inhibitor aminoglutethimide, for the first 2 years of therapy. For ABCSG Trial 6a, 
patients who were disease free at the end of Trial 6 were randomly assigned to receive either 3 years of 
anastrozole or no further treatment. Efficacy data were analyzed with the use of a Cox proportional 
hazards regression model with two-sided  P values and Kaplan – Meier curves, and tolerability data were 
estimated using logistic regression analysis with odds ratios and 95% confidence intervals (CIs). 
  Results  ABCSG Trial 6a included 856 patients. At a median follow-up of 62.3 months, women who received anas-
trozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, con-
tralateral breast cancer, or distant metastasis) compared with women who received no further treatment 
(n = 469; hazard ratio = 0.62; 95% CI = 0.40 to 0.96,  P = .031). Anastrozole was well tolerated, and no unex-
pected adverse events were reported. 
  Conclusions  These data confirm the benefit of extending adjuvant tamoxifen therapy beyond 5 years with anastrozole 
compared with no further treatment. Further research is required to define the optimum length of extended 
adjuvant therapy and to investigate the possibility of tailoring this period to suit different disease types. 
  J Natl Cancer Inst 2007;99: 1845 – 53 
 JNCI Journal of the National Cancer Institute Advance Access published December 11, 2007
1846   Articles | JNCI Vol. 99, Issue 24  |  December 19, 2007
The absolute survival benefit for women with ER – positive disease 
who received 5 years of adjuvant tamoxifen compared with women 
who did not was almost three times greater at 15 years of follow-up 
(9.2%) than at 5 years of follow-up (3.6%) ( 1 , 2 ). 
 A 5-year period for adjuvant monotherapy in postmenopausal 
women was adopted because of the risk – benefi t profi le of tamoxifen, 
rather than because an optimum length for adjuvant endocrine 
therapy had been determined. Current data indicate that approxi-
mately 10 years of adjuvant tamoxifen treatment does not produce 
additional overall survival benefi ts compared with 5 years of treat-
ment, partly because of the increased risk of thromboembolic disease 
( 1 ). In addition, the risk of endometrial cancer associated with 
tamoxifen use increases with treatment duration ( 1 , 3 , 4 ). Other 
studies have also failed to demonstrate a reduced risk of recurrence 
with more than 5 years of adjuvant tamoxifen ( 3 , 5 , 6 ). Clinical trials 
such as the Adjuvant Tamoxifen Treatment — Offer More? and 
Adjuvant Tamoxifen Longer Against Shorter trials are in progress 
to more accurately defi ne the advantages and disadvantages of 
different lengths of adjuvant tamoxifen therapy. However, in the 
meantime, the 5-year period of treatment has become standard for 
adjuvant therapy in postmenopausal women, regardless of the 
agent employed. 
 In recent years, aromatase inhibitors have become widely accepted 
as alternatives to tamoxifen as the standard adjuvant treatment for 
postmenopausal women with hormone-sensitive early-stage breast 
cancer. Five years of adjuvant treatment with the third-generation 
nonsteroidal aromatase inhibitor anastrozole is superior to tamoxifen 
treatment in postmenopausal women in terms of both effi cacy and 
safety, as demonstrated by data from the Arimidex, Tamoxifen, 
Alone or in Combination (ATAC) trial at a median follow-up of 
68 months ( 7 ). There are also effi cacy and safety benefi ts associated 
with switching to anastrozole in patients who are disease free after 
2 – 3 years of adjuvant tamoxifen therapy ( 8 – 11 ). 
 Data from the National Cancer Institute of Canada MA.17 trial 
showed that breast cancer recurrence was statistically signifi cantly 
( P <.001) reduced in patients who were disease free after 5 years of 
adjuvant treatment with tamoxifen by further treatment with letro-
zole, another third-generation nonsteroidal aromatase inhibitor 
( 12 ). Although this was the fi rst trial to demonstrate the benefi t of 
extending the period of adjuvant letrozole treatment beyond 
5 years, it was halted early at a median follow-up of 30 months. 
Thus, no long-term effi cacy or safety data are available from this 
randomized clinical investigation. 
 We sought to investigate the effi cacy of extended adjuvant 
therapy with anastrozole in breast cancer patients who remain 
recurrence free after 5 years of adjuvant tamoxifen. We conducted 
a randomized trial (Trial 6a) to compare extended adjuvant therapy 
with anastrozole for 3 years with no further treatment among 
women who had completed 5 years of adjuvant therapy in Austrian 
Breast and Colorectal Cancer Study Group (ABCSG) Trial 6. We 
examined recurrence-free and overall survival as well as tolerabil-
ity. ABCSG Trial 6 had found that adjuvant tamoxifen plus the 
aromatase inhibitor aminoglutethimide was not superior to adju-
vant tamoxifen alone in postmenopausal women with primary, 
hormone receptor – positive breast cancer ( 13 ). 
 Patients and Methods 
 Patients 
 ABCSG Trial 6a was a prospective randomized open-label clinical 
study that was a continuation of ABCSG Trial 6, which compared 5 
years of adjuvant tamoxifen (40 mg daily for the first 2 years, then 20 mg 
daily thereafter) with 5 years of adjuvant tamoxifen (40 mg daily for 
the first 2 years, then 20 mg daily thereafter) plus aminoglutethimide 
(250 mg daily for week 1, 375 mg daily for week 2, then 500 mg daily 
thereafter for the first 2 years of treatment) ( 13 ) ( Fig. 1 ). 
 Patients who were eligible for ABCSG Trial 6 (and, therefore, 
for ABCSG Trial 6a) were postmenopausal women in Austria with 
surgical treatment for histologically confi rmed, endocrine-responsive, 
primary unilateral stage I or II breast cancer (pT1 to pT3a) with 
negative or positive axillary nodes. Tumor stage was defi ned using 
the TNM (tumor – node – metastasis) classifi cation ( 14 ), and 
postmenopausal status was defi ned as amenorrhea for at least 
1 year or gonadotrophin levels in the postmenopausal range (i.e., 
a luteinizing hormone concentration of 2 – 105 pg/mL, a follicle-
stimulating hormone concentration of 2 – 151 pg/mL, and a pros-
taglandin E2 concentration of 2 – 210 pg/mL). Surgical treatment 
consisted of breast-conserving surgery, or modifi ed radical mastec-
tomy with obligatory negative margins plus complete axillary 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 A large clinical trial found that women who received 5 years of the 
nonsteroidal aromatase inhibitor letrozole after 5 years of adjuvant 
tamoxifen experienced a 42% reduction in the risk of recurrence 
compared with women who received placebo. However, early 
stoppage of that trial precluded assessments of the long-term effi-
cacy and safety of extended adjuvant treatment. 
 Study design 
 Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 
6a was a prospective randomized open-label clinical trial to com-
pare the efficacy and tolerability of extended adjuvant therapy with 
anastrozole for 3 years with no further treatment among patients 
who were disease free at the end of ABCSG Trial 6, which found 
that adjuvant tamoxifen plus the aromatase inhibitor aminoglu-
tethimide was not superior to adjuvant tamoxifen alone in hor-
mone receptor – positive postmenopausal breast cancer patients. 
 Contribution 
 At a median follow-up of more than 5 years, extended adjuvant 
therapy with 3 years of anastrozole after successful completion of 
5 years of tamoxifen reduced the risk of recurrence by 38% com-
pared with no further treatment. Anastrozole was well tolerated, 
and no unexpected adverse events were reported. 
 Implications 
 The more manageable side effect profile of anastrozole compared 
with tamoxifen may allow the duration of adjuvant treatment to 
extend beyond the 5-year period recommended for tamoxifen. 
 Limitations 
 A prerandomization procedure was used to randomly assign all eli-
gible patients in ABCSG Trial 6 (i.e., all those who remained in the 
trial and disease free) to an arm of Trial 6a to ensure that there 
would be no gap in treatment between completion of 5 years of pri-
mary adjuvant therapy and commencement of the extended study. 
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clearance, including complete level I and II dissection. Patients 
were required to have had histologic assessment of at least six axil-
lary nodes. Tumors were required to have ER and/or progesterone 
receptor levels of at least 10 fmol per milligram of cytosol protein 
by biochemical determination or to be positive by immunohisto-
chemical determination. 
 Patients were ineligible for both ABCSG Trial 6 and ABCSG 
Trial 6a if they displayed any evidence of metastatic disease (diag-
nosed according to local practice by x-ray of the chest wall, native 
x-ray, computed tomography scan, ultrasound, or other methods) 
or if they were premenopausal or had a previous diagnosis of 
malignant disease (except cured squamous cell skin carcinoma 
and early-stage cervical cancer). Other exclusion criteria included 
preoperative antineoplastic treatment and irradiation; negative or 
unknown hormone receptor status; general contraindications 
including hypersensitivity to tamoxifen or aminoglutethimide; 
more than 4 weeks between randomization and start of treatment 
in ABCSG Trial 6a; in situ carcinoma with or without Paget ’ s dis-
ease of the nipple; T4 tumor; infl ammatory breast cancer; negative 
or unknown receptor status; defi cient patient comprehension and/
or reliability; inadequate laboratory parameters; serious concomi-
tant disease rendering treatment impossible as per protocol; age 
greater than 80 years; Karnofsky Index greater than 3; septic com-
plications; systemic infections; bilateral ovariectomy; or radiother-
apy to ovaries. 
 Adjuvant treatment in ABCSG Trial 6 was initiated within 
6 weeks after surgery and lasted for 5 years or until disease recur-
rence or progression. All patients in ABCSG Trial 6 who had not 
experienced a recurrence by the end of 5 years of adjuvant therapy 
were eligible to participate in ABCSG Trial 6a and were randomly 
reassigned to receive anastrozole (1 mg daily) or no treatment for 
3 years, beginning within 6 weeks after completing 5 years of 
tamoxifen ( Fig. 1 ). We chose a 3-year duration for anastrozole 
treatment on the basis of fi nancial considerations and on our belief 
that 3 years of anastrozole should be suffi cient to achieve optimal 
reduction of circulating estrogen levels. 
 All patients provided written informed consent, and the study 
was performed in accordance with the Declaration of Helsinki. 
ABCSG Trials 6 and 6a were approved by the relevant ethics 
committees in Austria. ABCSG Trial 6a was registered at 
 www.clinicaltrials.gov with number NCT00300508. 
 Procedures and Assessments 
 Computer-assisted prerandomization for ABCSG Trial 6a was 
performed during Trial 6 and centrally at the ABCSG randomiza-
tion office (Vienna, Austria) and confirmed by the individual trial 
centers after patient’s informed consent was obtained during the 
ABCSG Trial 6 completion visit. Patients were allocated to receive 
anastrozole or no further treatment according to the minimization 
method of Pocock and Simon ( 15 ), with stratification by the follow-
ing prognostic factors: age, tumor size, tumor grade, number of 
involved nodes, locoregional treatment, adjuvant therapy, hormone 
receptor status, and participating trial center. 
 Patients who were randomly assigned to receive no further 
treatment underwent a physical examination, had laboratory serum 
parameters and tumor markers assessed, and were monitored for 
adverse events every 6 months for 5 years (i.e., up to the tenth year 
after surgery). Adverse events were defi ned as any adverse change 
in health or side effect that occurred while the patient was receiv-
ing treatment or within a prespecifi ed period after treatment. 
Serious adverse events were defi ned as any medical occurrence that 
results in death, is life threatening, requires inpatient hospitaliza-
tion or prolongation of existing hospitalization, results in persis-
tent or clinically signifi cant disability or incapacity, or as a 
congenital anomaly or birth defect in the children born to women 
after they participated in this study. 
 Patients who were randomly assigned to receive anastrozole 
underwent a physical examination and were monitored for adverse 
events every 3 months during treatment (i.e., up to the eighth year 
after surgery) and every 6 months during follow-up (i.e., up to the 
tenth year after surgery). Laboratory serum parameters and tumor 
markers were assessed every 3 months during the fi rst year of treat-
ment and every 6 months thereafter. Chest x-ray, abdominal ultra-
sound, mammography, and gynecologic examinations were 
performed annually throughout follow-up for both groups. 
 The primary endpoint for ABCSG Trial 6a was recurrence-free 
survival, which was defi ned as the interval between the start of 
anastrozole treatment or of the observation period (for the no 
further treatment group) and the fi rst evidence of locoregional 
recurrence, contralateral breast cancer, or distant metastasis. 
Locoregional recurrence was defi ned as recurrence in the ipsilat-
eral breast or chest wall or in the axillary nodes. Distant metastases 
included all distant lymph node recurrences (i.e., supraclavicular, 
mammaria internal, and contralateral axilla) and organ metastases. 
The secondary endpoints were overall survival, which was defi ned 
as the interval between the start of anastrozole treatment or of the 
observation period and death from any cause, and tolerability. 
 Statistical Analysis 
 All analyses were performed on an intention-to-treat basis. The 
effect of treatment on recurrence-free and overall survival was esti-
mated using a univariate Cox proportional hazards regression 
model ( 16 ). A multivariable Cox proportional hazards regression 
model was also calculated by including all covariates that showed a 
statistically significant effect in the corresponding univariate analy-
sis at the 5% level. Covariates that did not show a statistically sig-
nificant effect in the univariate analysis were considered to be 
irrelevant. Multivariable hazard ratios (HRs) and corresponding 
95% confidence intervals (CIs) were calculated. Survival was ana-
lyzed by the Kaplan – Meier method using the log-rank test ( 17 ). 
The proportionality assumption of the Cox model was investigated 
with a time-dependent exploratory variable, which was defined as 
treatment multiplied by the logarithm (base e) of the time to event 
(i.e., interaction term). A  P value from the Wald chi-squared statis-
tic for this variable of less than 5% would have constituted evidence 
of a departure from the proportionality assumption. There was no 
evidence of departure from proportionality at the 5% statistical 
significance level. 
 Additional analyses included a multiple Cox proportional haz-
ards regression model that adjusted for the following factors used 
in the randomization process: age, tumor size, tumor grade, num-
ber of involved nodes, locoregional treatment, adjuvant therapy, 
and hormone receptor status. Interaction terms between treatment 
and these factors were tested for statistical signifi cance. 
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 The main analysis of recurrence-free survival included the fi rst 
occurrence of locoregional cancer, contralateral breast cancer, or 
distant metastasis as recurrence. In a sensitivity analysis, however, 
patients who did not experience recurrence were censored at the 
last follow-up or at the date of diagnosis of a secondary cancer if 
this type of event occurred fi rst. We estimated that an initial target 
population of 1700 women was needed for the ABCSG 6a trial to 
have 85% power at a statistical signifi cance level of 5% to detect a 
30% reduction in recurrence with anastrozole. 
 Adverse events were only counted once per patient at the time 
they fi rst occurred and are described by their absolute frequencies 
and proportions. Differences in adverse event rates were estimated 
with odds ratios and corresponding 95% confi dence intervals from 
logistic regression analysis. 
 All  P values are two-sided and were considered to be statistically 
signifi cant if less than .05. All statistical analyses were performed 
using SAS software (version 8.02; SAS Institute Inc., Cary, NC). 
 Results 
 Patients 
 Fig. 1 shows the flow of patients through ABCSG Trials 6 and 6a. 
A total of 1135 women from ABCSG Trial 6 were eligible for ran-
domization in ABCSG Trial 6a; 575 women were randomly 
assigned to receive no further treatment, and 560 women were 
randomly assigned to receive 3 years of anastrozole. A total of 860 
women (470 of the 575 women randomly assigned to no further 
treatment and 390 of the 560 women randomly assigned to 3 years 
of anastrozole) gave written informed consent for entry into Trial 
6a. Four women (one in the no further treatment group and three 
in the anastrozole group) were ineligible for analysis because of 
liver metastases, hysterectomy, malignant melanoma, and undeter-
mined menopausal status. Of the 856 women eligible for analysis 
(of whom 469 were randomly assigned to no further treatment and 
387 to anastrozole), 406 (47.4%) had received tamoxifen plus ami-
noglutethimide and 450 (52.6%) had received tamoxifen alone as 
adjuvant treatment in Trial 6 ( Table 1 ). These 856 women were 
included in analyses of demographic characteristics, serious adverse 
events, and predefined adverse events. The imbalance in number 
of women in the two arms of ABCSG Trial 6a occurred because 
prerandomization for Trial 6a was performed during ABCSG 
Trial 6, whereas patients’ consent for Trial 6a was confirmed at the 
completion of ABCSG Trial 6 to prevent any gap in treatment 
between the completion of treatment in ABCSG Trial 6 and the 
commencement of ABCSG Trial 6a. Finally, because of missing 
data in ABCSG Trial 6a, 466 women in the no further treatment 
arm and 386 women in the anastrozole arm were available for pri-
mary outcome assessments (total n = 852). 
 Demographic data and disease characteristics for patients in 
ABCSG Trial 6a are shown in  Table 1 . At prerandomization for 
Trial 6a, the median age of the patients was 68.1 years (range = 51.8 –
 85.5 years). Median follow-up at this analysis was 62.3 months. 
 Efficacy 
 Women who received 3 years of anastrozole as extended adjuvant 
therapy experienced statistically significantly fewer recurrences 
(i.e., a first occurrence of locoregional, contralateral, or distant 
metastatic events) than women who received no extended adjuvant 
treatment; these women had a 38% reduced risk of recurrence 
(HR = 0.62, 95% CI = 0.40 to 0.96,  P = .031) ( Table 2 ). The recur-
rence rate was 11.8% for patients in the no further treatment group 
at 10 years after surgery, compared with 7.1% for patients receiving 
adjuvant treatment with anastrozole. Kaplan – Meier curves for 
recurrence-free survival are presented in  Fig. 2 . 
 The incidence of recurrence events is shown in  Table 2 . The 
difference in assessment intervals between the two groups had no 
effect on the total hazard ratio of events (data not shown). When 
the recurrence events were considered separately by type, only the 
incidence of distant metastatic events differed statistically signifi -
cantly between the study arms (35 events for the no further treat-
ment arm versus 16 events for the anastrozole arm; HR = 0.53, 
95% CI = 0.29 to 0.96,  P = .034). The Kaplan – Meier curves for 
distant metastatic recurrence–free survival began to separate at 
approximately 20 months, revealing an advantage for the women 
who received anastrozole ( Fig. 3 ). In addition, the incidence of 
recurrence events in Trial 6a was lower in patients who had 
received tamoxifen plus aminoglutethimide in ABCSG Trial 6 
(32 events in 404 patients) than in patients who had received 
tamoxifen alone (55 events in 448 patients) (HR = 0.64, 95% CI = 
0.41 to 0.98;  P = .042). 
  
 Fig. 1 .  CONSORT trial fl ow diagram for Austrian Breast and Colorectal 
Cancer Study Group (ABCSG) Trials 6 and 6a. 
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 The forest plot in  Fig. 4 shows the risk of recurrence stratifi ed 
by age, nodal status, tumor grade, hormone receptor status, and 
type of adjuvant therapy received in ABCSG Trial 6. This sub-
group analysis demonstrated that among patients with ER-
positive, PgR-positive tumors (664/852), those who received 
anastrozole had a lower risk of recurrence than those who received 
no further treatment (HR = 0.32, 95% CI = 0.18 to 0.58,  P <.001). 
The hazard ratios of recurrence calculated for patients who 
received tamoxifen only versus tamoxifen plus aminoglutethimide 
are based on comparable numbers of patients and suggest a statisti-
cally signifi cantly better outcome, in terms of recurrence risk, for 
patients who did not receive aminoglutethimide during their adju-
vant therapy in ABCSG Trial 6 (HR = 0.40, 95% CI = 0.22 to 0.73, 
 P = .002). This subgroup analysis also suggests that among a small 
number of patients with ER-positive, PgR-negative tumors 
(139/852), those who received anastrozole had a greater risk of 
recurrence than those who received no further treatment (HR = 
3.49, 95% CI = 1.31 to 9.30,  P = .008). 
 Despite the improvement in recurrence-free survival, there was 
no statistically signifi cant difference in overall survival between 
study arms (55 deaths [11.7%] for the no further treatment arm 
versus 40 deaths [10.3%] for the anastrozole arm; HR of death 
from any cause = 0.89, 95% CI = 0.59 to 1.34,  P = .570). In the no 
further treatment arm, 25 deaths were breast cancer – related and 
30 were due to other causes. In the anastrozole arm, 12 deaths 
were breast cancer – related and 28 were due to other causes. 
 Overall, 237 women withdrew from ABCSG Trial 6a before the 
3-year period ended (128 [33.1%] from the anastrozole group and 
109 [23.2%] from the control group). Adverse events accounted for 
45 withdrawals from the anastrozole arm of the trial (two of these 
withdrawals were also due to recurrence) but for none of the 
withdrawals from the no further treatment arm. There were 25 and 
42 withdrawals due to disease recurrence or the appearance of a 
secondary tumor in the anastrozole arm and no further treatment 
arm, respectively, and eight and six additional deaths, respectively. 
 Tolerability 
 Overall, 13 serious adverse events occurred during ABCSG Trial 6a 
(seven in the anastrozole arm and six in the no further treatment 
arm) ( Table 3 ). Of these events, only one in the anastrozole arm 
(fracture) was considered by the investigators as being related to 
study treatment. 
 The incidences of predefi ned adverse events by treatment 
group are shown in  Table 4 . Anastrozole therapy was well toler-
ated, and the adverse events that were experienced by patients were 
as expected in view of available anastrozole tolerability data. All of 
the adverse events occurred more frequently in patients treated 
with anastrozole than in patients who received no further treat-
ment. The differences between the study arms were highly statisti-
cally signifi cant ( P <.001) for hot fl ushes; asthenia, somnolence; 
allergy, cutaneous toxicity, skin rash; hair loss; and nausea (all 
grade 1 toxic effects). 
 Discussion 
 Our data show that extended adjuvant therapy with 3 years of anas-
trozole after successful completion of 5 years of tamoxifen statistically 
 Table 1 .  Demographic and disease characteristics of patients 





3 y of 
anastrozole 
(n = 387) 
 Median age, y (range) 68.5 (51.8 – 85.5) 67.8 (51.8 – 83.2) 
 Involved nodes, No. (%)  
  None 323 (68.9) 255 (65.9) 
  1 – 3 112 (23.9) 104 (26.9) 
  4 – 10 27 (5.8) 22 (5.7) 
  >10 7 (1.5) 6 (1.6) 
 Tumor size † , No. (%)  
  T1 296 (63.1) 241 (62.3) 
  T2 166 (35.4) 137 (35.4) 
  T3 7 (1.5) 9 (2.3) 
 Tumor grade ‡ , No. (%)  
  G1 86 (18.3) 60 (15.5) 
  G2 256 (54.6) 220 (56.8) 
  G3 92 (19.6) 79 (20.4) 
  Gx 35 (7.5) 28 (7.2) 
 Primary therapy, No. (%)  
  Breast-conserving surgery 266 (56.7) 222 (57.4) 
  Modified radical mastectomy 203 (43.3) 165 (42.6) 
 Pretreatment § , No. (%)  
  Tamoxifen alone 240 (51.2) 210 (54.3) 
  Tamoxifen plus 
   aminoglutethimide
229 (48.8) 177 (45.7) 
 ER/PgR status, No. (%)  
  Positive/positive 359 (76.5) 309 (79.8) 
  Positive/negative 87 (18.6) 52 (13.4) 
  Negative/positive 8 (1.7) 10 (2.6) 
  ER or PgR status unknown 15 (3.2) 16 (4.1) 
 *  ABCSG = Austrian Breast and Colorectal Cancer Study Group; ER = estrogen 
receptor; PgR = progesterone receptor. 
 †  T1 = 0 to  ≤ 2 cm; T2 > 2 to  ≤ 5 cm; T3 > 5 cm. 
 ‡  G1 = well differentiated; G2 = moderately differentiated; G3 = poorly 
differentiated; Gx = unknown differentiation. 
 §  Adjuvant treatment received in ABCSG Trial 6. 
 Table 2 .  Incidence of recurrence events in ABCSG Trial 6a at 5 years * 
 Event
No further treatment 
(n = 466), No. (%)
3 y of anastrozole 
(n = 386), No. (%)
Total (n = 852), 
No. (%) HR (95% CI)  P † 
 Total 57 (12.2) 30 (7.8) 87 (10.2) 0.62 (0.40 to 0.96) .031 
 Locoregional 15 (3.2) 10 (2.6) 25 (2.9) 0.79 (0.36 to 1.76) .564 
 Distant metastatic 35 (7.5) 16 (4.1) 51 (6.0) 0.53 (0.29 to 0.96) .034 
 Contralateral breast cancer 11 (2.4) 6 (1.6) 17 (2.0) 0.67 (0.25 to 1.80) .422 
 *  ABCSG = Austrian Breast and Colorectal Cancer Study Group; HR = hazard ratio; CI = confidence interval. 
 †  Data analyzed using Cox proportional hazards regression model with two-sided  P values. 
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significantly reduced the risk of recurrence by 38% compared with 
no further treatment. This finding is in accordance with results of 
the larger MA.17 trial, in which women who received 5 years of 
letrozole after 5 years of adjuvant tamoxifen experienced a 42% 
reduction in the risk of recurrence compared with women who 
received placebo ( 12 ). Our data indicate that extended adjuvant 
endocrine therapy with anastrozole is a valid therapeutic option for 
breast cancer patients who have completed 5 years of adjuvant 
tamoxifen. Furthermore, with a median follow-up of more than 
5 years, these data can be considered to be mature. 
 A potential study limitation is that prerandomization is not 
standard practice. We chose to randomly assign all eligible 
patients in ABCSG Trial 6 (i.e., all those who remained in the trial 
and disease free) to an arm of Trial 6a to ensure that there would 
be no gap in treatment between completion of 5 years of primary 
adjuvant therapy (ABCSG Trial 6) and commencement of the 
extended study (ABCSG Trial 6a). However, the number of patients 
in the prerandomized treatment groups who gave consent for 
Trial 6a differed between the groups. In almost all cases, the 
decision not to enter Trial 6a was because the patient felt that 5 
years of adjuvant treatment was suffi cient. Very few patients 
became ineligible because they experienced an event between the 
time of the central randomization and the fi nal visit for Trial 6. 
However, the baseline characteristics for the anastrozole and no 
further treatment groups were well balanced, which suggests that 
prerandomization did not cause suffi cient bias to invalidate the 
study conclusions. 
 No conclusion should be drawn regarding our observation of 
an apparent improvement in outcome for ER-positive and PgR-
positive patients compared with ER-positive and PgR-negative 
  
 Fig. 2 .  Kaplan – Meier curves for recurrence-free survival in the anastro-
zole and no further treatment arms of Austrian Breast and Colorectal 
Cancer Study Group Trial 6a. In total, 852 women were analyzed for the 
primary effi cacy outcome. HR = hazard ratio; CI = confi dence interval. 
  
 Fig. 3 .  Kaplan – Meier curves for distant metastatic recurrence–free sur-
vival in the anastrozole and no further treatment arms of Austrian 
Breast and Colorectal Cancer Study Group Trial 6a. HR = hazard ratio; 
CI = confi dence interval. 
 Fig. 4 .  Forest plot of risk of recur-
rence stratifi ed by subgroups. The 
 squares represent the point esti-
mate of the hazard ratio (HR), the 
 lines are the 95% confi dence inter-
vals (CIs), and the size of the  square 
is proportional to the precision of 
the estimate (number of patients, 
number of events, and variance). 
The  vertical dashed line indicates 
the no effect point, and the  solid 
vertical line , the overall treatment 
effect. * = Data for four patients 
were missing at the time of the 
analysis; † = ER/PgR status is 
unknown in 31 patients; ER = estro-
gen receptor; PgR = progesterone 
receptor. 
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patients because of the very small number of patients in the latter 
group. The same applies to the fi nding that extended anastrozole 
treatment provided no additional benefi t for women who had 
received aminoglutethimide as part of their adjuvant therapy com-
pared with those who had not. Subgroup analysis should be inter-
preted with caution and can lead to a substantial amount of 
misinterpretation because it is frequently based on small numbers 
and thus has low statistical power. For example, in some small 
subgroups in the MA.17 trial, a benefi t was seen for patients 
treated with placebo compared with those who received extended 
adjuvant letrozole treatment ( 12 ). In addition, other studies that 
have examined the effect of aromatase inhibitor treatment in sub-
groups of patients according to receptor status have suggested that 
there is no real difference in treatment effect according to receptor 
status ( 18 , 19 ). 
 The results from ABCSG Trial 6 showed no statistically signifi -
cant difference in 5-year disease-free survival for adjuvant treat-
ment with tamoxifen plus aminoglutethimide compared with 
tamoxifen alone ( 13 ), indicating that 2 years of this combined adju-
vant therapy did not improve the prognosis of patients compared 
with tamoxifen monotherapy. However, it is possible that prior 
exposure to the aromatase inhibitor aminoglutethimide in ABCSG 
Trial 6 may have, to some extent, reduced the effi cacy of subse-
quent therapy with a second aromatase inhibitor (anastrozole) 
in this study. Breast carcinomas can develop resistance to the 
estrogen-deprived environment created by aromatase inhibitor 
treatment ( 20 ), which may explain the difference in the risk of 
recurrence seen between adjuvant pretreatment populations in the 
Trial 6a subgroup analysis. In this context, it is interesting that data 
from patients with advanced breast cancer suggest that nonsteroidal 
aromatase inhibitors can have a clinical benefi t (defi ned as complete 
responses, partial responses, and disease stabilization for at least 24 
weeks) after disease progression occurs during treatment with a 
steroidal aromatase inhibitor ( 21 ). However, our data cannot pro-
vide a detailed assessment of the effect of prior aminoglutethimide 
therapy on the effi cacy of subsequent aromatase inhibitor treatment 
because ABCSG Trial 6a did not examine this comparison. The 
lower incidence of recurrence events in Trial 6a in patients who had 
received tamoxifen plus aminoglutethimide in ABCSG Trial 6 
versus in those who had received tamoxifen alone could refl ect a 
carryover effect of aminoglutethimide in Trial 6. However, there 
 Table 3 .  Incidence of serious adverse events during ABCSG Trial 6a* 




3 y of 
anastrozole 
(n = 387) 
 Fractures, No. (%) 5 (1.1) 3 (0.8) 
 Thrombosis, No. (%) 1 (0.2) 2 (0.5) 
 Embolism, No. (%) 0 1 (0.3) 
 Myocardial infarction, No. (%) 0 1 (0.3) 
 * ABCSG = Austrian Breast and Colorectal Cancer Study Group. 
 Table 4 .  Incidence of predefined adverse events during ABCSG Trial 6a * 
 Adverse event Grade
No further 
treatment 
(n = 469), 
No. (%)
3 years of 
anastrozole 
(n = 387), 
No. (%)
Cumulative data for grade 1 – 4 and 2 – 4 adverse events † 
 No further 
treatment 
(n = 469), 
No. (%)
3 years of 
anastrozole 
(n = 387), 
No. (%) OR (95% CI)  P 
 Hot flushes 1 105 (22.4) 151 (39.0) 105 (22.4) 151 (39.0) 2.44 (1.80 to 3.31) <.001 
 Asthenia, somnolence 1 8 (1.7) 20 (5.2) 20 (4.3) 41 (10.6) 2.82 (1.62 to 4.90) <.001 
 2 11 (2.3) 15 (3.9) 12 (2.6) 21 (5.4) 2.30 (1.12 to 4.75) .02 
 3 1 (0.2) 3 (0.8)  
 4 0 (0.0) 3 (0.8)  
 Allergy, cutaneous toxicity, skin rash 1 5 (1.1) 17 (4.4) 8 (1.7) 29 (7.5) 4.93 (2.23 to 10.93) <.001 
 2 3 (0.6) 7 (1.8) 3 (0.6) 12 (3.1) 5.23 (1.47 to 18.69) .011 
 3 0 (0.0) 4 (1.0)  
 4 0 (0.0) 1 (0.3)  
 Hair loss 1 8 (1.7) 19 (4.9) 10 (2.1) 35 (9.0) 4.83 (2.36 to 9.90) <.001 
 2 2 (0.4) 11 (2.8) 2 (0.4) 16 (4.1) 10.61 (2.42 to 46.43) .002 
 3 0 (0.0) 5 (1.3)  
 Diarrhea 1 5 (1.1) 7 (1.8) 12 (2.6) 16 (4.1) 1.73 (0.81 to 3.70) .159 
 2 7 (1.5) 7 (1.8) 7 (1.5) 9 (2.3) 1.65 (0.61 to 4.48) .32 
 3 0 (0.0) 1 (0.3)  
 4 0 (0.0) 1 (0.3)  
 Nausea 1 10 (2.1) 17 (4.4) 11 (2.3) 32 (8.3) 3.97 (1.97 to 7.99) <.001 
 2 1 (0.2) 11 (2.8) 1 (0.2) 15 (3.9) 19.88 (2.61 to 151.24) .004 
 3 0 (0.0) 3 (0.8)  
 4 0 (0.0) 1 (0.3)  
 Vaginal bleeding 1 1 (0.2) 1 (0.3) 1 (0.2) 3 (0.8) 3.84 (1.40 to 37.06) .245 
 2 0 (0.0) 2 (0.5) 0 (0.0) 2 (0.5)  –  – 
 Vaginal discharge 1 13 (2.8) 23 (5.9) 13 (2.8) 23 (5.9) 2.34 (1.17 to 4.68) .017 
 Vaginal dryness 1 32 (6.8) 45 (11.6) 32 (6.8) 45 (11.6) 1.90 (1.18 to 3.07) .008 
 Bone pain (including joint pain) 1 86 (18.3) 95 (24.5) 86 (18.3) 95 (24.5) 1.55 (1.11 to 2.17) .009 
 *  ABCSG = Austrian Breast and Colorectal Cancer Study Group; OR = odds ratio; CI = confidence interval;  – = not applicable. 
 †  Odds ratios on the same line as grade 1 event include all adverse events; those on the same line as grade 2 events include grade 2 – 4 adverse events. 
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was no statistically signifi cant difference in disease-free survival 
between therapy arms in Trial 6 ( 13 ). 
 We cannot draw fi rm conclusions from the trends indicated in 
the ABCSG Trial 6a subgroup analysis without further investiga-
tion in prospectively designed clinical trials. Because aminoglu-
tethimide is no longer commonly used in the adjuvant setting, such 
studies are unlikely to be initiated. However, these effi cacy data 
indicate that it may be appropriate to investigate the effects of giv-
ing a different aromatase inhibitor in the extended adjuvant setting 
from that given as adjuvant therapy. 
 The tolerability profi le of anastrozole observed in ABCSG 
Trial 6a is consistent with that observed in the 68-month com-
pleted treatment analysis of the ATAC trial ( 7 ). The low incidence 
of fractures in both arms of this study may refl ect the protective 
effect of 5 years of tamoxifen on bone health ( 22 ). 
 The impact of our data on current practice is unclear. 
However, the introduction of an aromatase inhibitor following 
adjuvant therapy with tamoxifen has been addressed in an 
American Society of Clinical Oncology technology assessment on 
adjuvant use of aromatase inhibitors ( 23 ), which recommends the 
use of the aromatase inhibitor “that has been studied in the set-
ting most closely approximating any individual patient’s clinical 
circumstance.” To date, anastrozole has shown superiority over 
tamoxifen in both the primary adjuvant and switched adjuvant 
settings (i.e., completion of the 5-year adjuvant treatment period 
with an aromatase inhibitor rather than continuing with tamoxi-
fen after 2 years of treatment) ( 7 – 9 , 11 ). In addition, the data pre-
sented here highlight the potential of anastrozole for use in the 
extended adjuvant setting. More mature data are awaited for the 
primary adjuvant setting with anastrozole (ATAC trial) and for 
the primary adjuvant and sequencing settings with letrozole (BIG 
1 – 98 trial). To date, the only data available for exemestane are in 
the switched adjuvant setting from the Intergroup Exemestane 
Study at a mean follow-up of 55.7 months ( 24 ). Therefore, of the 
three third-generation aromatase inhibitors, anastrozole cur-
rently has the most comprehensive dataset relating to adjuvant 
therapy. 
 The apparent benefi t of extended adjuvant therapy with aroma-
tase inhibitors raises the question of the optimal duration of adju-
vant endocrine treatment with aromatase inhibitors. This question 
is being addressed by the ongoing Secondary Adjuvant Long-term 
Study with Arimidex study, which compares 2 years with 5 years of 
extended adjuvant anastrozole after 5 years of exposure to adjuvant 
endocrine therapy (current recruitment exceeds 2000 patients). 
The more manageable side effect profi le of anastrozole compared 
with tamoxifen may allow the duration of adjuvant treatment to 
extend beyond the 5-year period recommended for tamoxifen. 
Consequently, we may now be in a position to investigate the pos-
sibility of tailoring the duration of adjuvant treatment to the 
requirements of individual patients or disease types. 
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